Off-target effects of an insect cell-expressed influenza HA-pseudotyped Gag-VLP preparation in limiting postinfluenza Staphylococcus aureus infections.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
Read More Add to Saved list
  • Additional Information
    • Source:
      Publisher: Elsevier Science Country of Publication: Netherlands NLM ID: 8406899 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1873-2518 (Electronic) Linking ISSN: 0264410X NLM ISO Abbreviation: Vaccine Subsets: MEDLINE
    • Publication Information:
      Publication: Amsterdam, The Netherlands : Elsevier Science
      Original Publication: [Guildford, Surrey, UK] : Butterworths, [c1983-
    • Subject Terms:
      Influenza Vaccines/*administration & dosage ; Influenza, Human/*prevention & control ; Staphylococcal Infections/*prevention & control ; Vaccines, Virus-Like Particle/*administration & dosage; Animals ; Female ; Hemagglutinin Glycoproteins, Influenza Virus/immunology ; Humans ; Influenza A Virus, H1N1 Subtype/immunology ; Influenza Vaccines/immunology ; Influenza, Human/complications ; Insecta ; Mice ; Mice, Inbred BALB C ; Superinfection/prevention & control ; Vaccination ; Vaccines, Virus-Like Particle/immunology ; Virus Replication/immunology
    • Abstract:
      Clinical and historical data underscore the ability of influenza viruses to ally with Staphylococcus aureus and predispose the host for secondary bacterial pneumonia, which is a leading cause of influenza-associated mortality. This is fundamental because no vaccine for S. aureus is available and the number of antibiotic-resistant strains is alarmingly rising. Hence, this leaves influenza vaccination the only strategy to prevent postinfluenza staphylococcal infections. In the present work, we assessed the off-target effects of a Tnms42 insect cell-expressed BEI-treated Gag-VLP preparation expressing the HA of A/Puerto Rico/8/1934 (H1N1) in preventing S. aureus superinfection in mice pre-infected with a homologous or heterologous H1N1 viral challenge strain. Our results demonstrate that matched anti-hemagglutinin immunity elicited by a VLP preparation may suffice to prevent morbidity and mortality caused by lethal secondary bacterial infection. This effect was observed even when employing a single low antigen dose of 50 ng HA per animal. However, induction of anti-hemagglutinin immunity alone was not helpful in inhibiting heterologous viral replication and subsequent bacterial infection. Our results indicate the potential of the VLP vaccine approach in terms of immunogenicity but suggest that anti-HA immunity should not be considered as the sole preventive method for combatting influenza and postinfluenza bacterial infections.
      (Copyright © 2019 The Authors. Published by Elsevier Ltd.. All rights reserved.)
    • Grant Information:
      I 3490 Austria FWF_ Austrian Science Fund FWF
    • Contributed Indexing:
      Keywords: Influenza; Secondary bacterial infection; Staphylococcus aureus; VLP vaccine; Vaccine off-target effects
    • Accession Number:
      0 (Hemagglutinin Glycoproteins, Influenza Virus)
      0 (Influenza Vaccines)
      0 (Vaccines, Virus-Like Particle)
    • Publication Date:
      Date Created: 20191114 Date Completed: 20210210 Latest Revision: 20220810
    • Publication Date:
      20221213
    • Accession Number:
      10.1016/j.vaccine.2019.10.083
    • Accession Number:
      31718898